BackgroundCheck.run
Search For

Vidyasagar Sagar Vuligonda, 64Lake Forest, CA

Known as:
Vidyasagar S Vuligonda Vidya Sagar Vuligonda Vidya S Vuligonda Vidyasagr Vuligonda Zidyasagar Vuligonda Sager Vuligonda Vuligonda Vidyasagar
Related to:
Tej Vuligonda 28

Vidyasagar Vuligonda Phones & Addresses

Lake Forest, CA   

Corona, CA   

2 Green Holw, Irvine, CA 92620    714-7307171    949-8574874   

Denton, TX   

Orange, CA   

Mountain View, CA   

Get Report
Control this profile

Mentions for Vidyasagar Sagar Vuligonda

Publications & IP owners

Us Patents

O- Or S- Substituted Tetrahydronaphthalene Derivatives Having Retinoid And/Or Retinoid Antagonist-Like Biological Activity

US Patent:
6344561, Feb 5, 2002
Filed:
Dec 11, 2000
Appl. No.:
09/735172
Inventors:
Vidyasagar Vuligonda - Irvine CA
Min Teng - Aliso Viejo CA
Richard L. Beard - Newport Beach CA
Alan T. Johnson - Rancho Santa Margarita CA
Yuan Lin - Walnut CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
C07D21170
US Classification:
546315, 546318, 546342
Abstract:
Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Acetylenes Disubstituted With A 5 Alkyl, Aryl Or Heteroaryl Substituted Dihydronaphthyl Group And With An Aryl Or Heteroaryl Group Having Retinoid-Like With An Aryl Or Heteroaryl Group Having Retinoid-Like Biological Activity

US Patent:
6355806, Mar 12, 2002
Filed:
Sep 16, 1999
Appl. No.:
09/398613
Inventors:
Alan T. Johnson - Rancho Santa Margarita CA
Min Teng - Aliso Viejo CA
Vidyasagar Vuligonda - Irvine CA
Richard L. Beard - Newport Beach CA
Samuel J. Gillett - Albany CA
Tien T. Duong - Irvine CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergen Sales, Inc. - Irvine CA
International Classification:
C07D21170
US Classification:
546348, 548202, 548215, 5483335, 549 80, 549506, 544239, 544335, 544406
Abstract:
Compounds of the formula wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.

Method For Inhibiting Gene Expression Promoted By Ap1 Protein With Rar Selective Retinoids And Method For Treatment Of Diseases And Conditions With Such Retinoids

US Patent:
6369100, Apr 9, 2002
Filed:
Jan 13, 2000
Appl. No.:
09/482589
Inventors:
Sunil Nagpal - Irvine CA
Tae K. Song - Long Beach CA
Vidyasagar Vuligonda - Irvine CA
Jyoti Athanikar - Irvine CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
A61K 4312
US Classification:
514460, 514336
Abstract:
Retinoid compounds which repress expression of the gene promoted by AP1 protein but which do not significantly activate expression of the genes having RA-responsive elements in their promoter region through RAR and RAR receptor subtypes, are used, with reduced side effects, for treating diseases and conditions which are responsive to therapy with retinoids.

Benzofuran, Indole Or Benzothiophene 2,4-Pentadienoic Acid Derivatives Having Selective Activity For Retinoid X (Rxr) Receptors

US Patent:
6388105, May 14, 2002
Filed:
Sep 27, 2001
Appl. No.:
09/967130
Inventors:
Vidyasagar Vuligonda - Irvine CA
Roshantha A. Chandraratna - Laguna Hills CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
C07D30779
US Classification:
549471, 5462774, 5462811, 5462841, 548469, 549 58
Abstract:
Compounds of the formula Where the variables are defined as in the specification, are selective agonists of RXR retinoid receptors.

2,4-Pentadienoic Acid Derivatives Having Selective Activity For Retinoid X (Rxr) Receptors

US Patent:
6403638, Jun 11, 2002
Filed:
Mar 21, 2000
Appl. No.:
09/532677
Inventors:
Vidyasagar Vuligonda - Irvine CA
Kwok Yin Tsang - Irvine CA
Jayasree Vasudevan - Irvine CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
A61K 3121
US Classification:
514457, 514531, 514557, 514569, 514570, 514510, 549102, 549124, 549362, 549407, 549408, 549548, 549549, 549551, 560 20, 560 21, 560 23, 560102, 560124, 562433, 562434, 562462, 562466, 562469, 562492
Abstract:
Compounds having the formulas below, where R is H, lower alkyl, or a pharmaceutically acceptable salt, and where R represents i-propyl, t-butyl or n-butyl groups, have selective RXR retionoid agonist activity.

O- Or S-Substituted Tetrahydronaphthalene Derivatives Having Retinoid And/Or Retinoid Antagonist-Like Biological Activity

US Patent:
6465663, Oct 15, 2002
Filed:
Jul 6, 2001
Appl. No.:
09/900593
Inventors:
Vidyasagar Vuligonda - Irvine CA
Min Teng - Aliso Viejo CA
Richard L. Beard - Newport Beach CA
Alan T. Johnson - Rancho Santa Margarita CA
Yuan Lin - Walnut CA
Roshantha A. Chandraratna - Mission Voejo CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
C07D40900
US Classification:
549 60
Abstract:
Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Synthesis And Use Of Retinoid Compounds Having Negative Hormone And/Or Anatgonist Activities

US Patent:
6469028, Oct 22, 2002
Filed:
Mar 28, 2001
Appl. No.:
09/821673
Inventors:
Elliott S. Klein - Marina del Rey CA
Alan T. Johnson - Rancho Santa Margarita CA
Andrew M. Standeven - Corona del Mar CA
Richard L. Beard - Newport Beach CA
Samuel J. Gillett - Albany CA
Tien T. Duong - Irvine CA
Sunil Nagpal - Lake Forest CA
Vidyasagar Vuligonda - Irvine CA
Min Teng - Aliso Viejo CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
C07D21514
US Classification:
514311, 514314, 514432, 514456, 546167, 546168, 549 23, 549362
Abstract:
Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.

Synthesis And Use Of Retinoid Compounds Having Negative Hormone And/Or Antagonist Activities

US Patent:
6521624, Feb 18, 2003
Filed:
Mar 23, 2000
Appl. No.:
09/535042
Inventors:
Elliott S. Klein - Marina del Ray CA
Alan T. Johnson - Rancho Santa Margarita CA
Andrew M. Standeven - Corona del Mar CA
Richard L. Beard - Newport Beach CA
Samuel J. Gillett - Albany CA
Tien T. Duong - Irvine CA
Sunil Nagpal - Lake Forest CA
Vidyasagar Vuligonda - Irvine CA
Min Teng - Aliso Viejo CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31495
US Classification:
514253, 514311, 514432, 514453
Abstract:
Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.